Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 2, 2014, Pages 524-538

  Wagner, Tobias ^a   Brand, Peter ^a   Heinzel, Thorsten ^a   Krämer, Oliver H ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cancer; HDAC inhibitors; HDAC2; P53; RLIM; Sumoylation

Indexed keywords

APC PROTEIN; AR 42; BRD 8430; BUTYRIC ACID; CELASTROL; CG 1521; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; ENTINOSTAT; EPIRUBICIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; JW 1521; LIM PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PANOBINOSTAT; PROTEIN BAX; PROTEIN P53; PROTEIN TYROSINE KINASE A; PUMA PROTEIN; RING FINGER PROTEIN; ROMIDEPSIN; TAMOXIFEN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANIMAL MODEL; APOPTOSIS; BINDING SITE; BREAST CANCER; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; ENZYME INHIBITION; ENZYME REPRESSION; EPIGENETICS; EWING SARCOMA; FEEDBACK SYSTEM; GENE EXPRESSION; GENE OVEREXPRESSION; GYNECOLOGIC CANCER; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HISTONE UBIQUITINATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MOUSE; NONHUMAN; PANCREAS CANCER; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STABILITY; PROTEIN TARGETING; REVIEW; SARCOMA; SKIN CANCER; SOLID TUMOR; STOMACH CANCER; SUMOYLATION; ACETYLATION; ANIMAL; ENZYMOLOGY; NEOPLASM; PHYSIOLOGY;

ACETYLATION; ANIMALS; CARCINOGENESIS; HISTONE DEACETYLASE 2; HUMANS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908592908     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.07.010     Document Type: Review

References (211)

1. Brandl A., Heinzel T., Krämer O.H. Histone deacetylases: salesmen and customers in the post-translational modification market. Biol. Cell. 2009, 101:193-205.
2. Krämer O.H. HDAC2: a critical factor in health and disease. Trends Pharmacol. Sci. 2009, 30:647-655.
3. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009, 280:168-176.
4. Witt O., Deubzer H.E., Milde T., Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett. 2009, 277:8-21.
5. Bug G., Ritter M., Wassmann B., Schoch C., Heinzel T., Schwarz K., Romanski A., Krämer O.H., Kampfmann M., Hoelzer D., Neubauer A., Ruthardt M., Ottmann O.G. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005, 104:2717-2725.
6. Munster P.N., Marchion D., Thomas S., Egorin M., Minton S., Springett G., Lee J.H., Simon G., Chiappori A., Sullivan D., Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br. J. Cancer 2009, 101:1044-1050.
7. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 2010, 6:238-243.
8. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
9. Müller S., Krämer O.H. Inhibitors of HDACs-effective drugs against cancer?. Curr. Cancer Drug Targets 2010, 10:210-228.
10. Spange S., Wagner T., Heinzel T., Krämer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 2009, 41:185-198.
11. Buchwald M., Krämer O.H., Heinzel T. HDACi-targets beyond chromatin. Cancer Lett. 2009, 280:160-167.
12. Matthews G.M., Newbold A., Johnstone R.W. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv. Cancer Res. 2012, 116:165-197.
13. Bradner J.E., Mak R., Tanguturi S.K., Mazitschek R., Haggarty S.J., Ross K., Chang C.Y., Bosco J., West N., Morse E., Lin K., Shen J.P., Kwiatkowski N.P., Gheldof N., Dekker J., DeAngelo D.J., Carr S.A., Schreiber S.L., Golub T.R., Ebert B.L. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:12617-12622.
14. Mercurio C., Minucci S., Pelicci P.G. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol. Res. 2010, 62:18-34.
15. Botrugno O.A., Santoro F., Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett. 2009, 280:134-144.
16. Yang X.J., Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 2008, 9:206-218.
17. Beckerman R., Prives C. Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol. 2010, 2:a000935.
18. Gu B., Zhu W.G. Surf the post-translational modification network of p53 regulation. Int. J. Biol. Sci. 2012, 8:672-684.
19. Gottlieb E., Vousden K.H. p53 regulation of metabolic pathways. Cold Spring Harb. Perspect. Biol. 2010, 2:a001040.
20. Rivlin N., Brosh R., Oren M., Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2011, 2:466-474.
21. Meek D.W., Anderson C.W. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb. Perspect. Biol. 2009, 1:a000950.
22. Schneider G., Krämer O.H. NFkappaB/p53 crosstalk-a promising new therapeutic target. Biochim. Biophys. Acta 2011, 1815:90-103.
23. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
24. Sun J.M., Chen H.Y., Davie J.R. Differential distribution of unmodified and phosphorylated histone deacetylase 2 in chromatin. J. Biol. Chem. 2007, 282:33227-33236.
25. Li P., Wang D., Yao H., Doret P., Hao G., Shen Q., Qiu H., Zhang X., Wang Y., Chen G., Wang Y. Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 2010, 29:3153-3162.
26. Li D.Q., Pakala S.B., Reddy S.D., Ohshiro K., Peng S.H., Lian Y., Fu S.W., Kumar R. Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAF1-proliferating cell nuclear antigen pathway. J. Biol. Chem. 2010, 285:10044-10052.
27. Brooks C.L., Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011, 2:456-462.
28. Kruse J.P., Gu W. Modes of p53 regulation. Cell 2009, 137:609-622.
29. Brandl A., Wagner T., Uhlig K.M., Knauer S.K., Stauber R.H., Melchior F., Schneider G., Heinzel T., Krämer O.H. Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J. Mol. Cell Biol. 2012, 4:284-293.
30. Chan W.M., Siu W.Y., Lau A., Poon R.Y. How many mutant p53 molecules are needed to inactivate a tetramer?. Mol. Cell. Biol. 2004, 24:3536-3551.
31. Terui T., Murakami K., Takimoto R., Takahashi M., Takada K., Murakami T., Minami S., Matsunaga T., Takayama T., Kato J., Niitsu Y. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res. 2003, 63:8948-8954.
32. Knights C.D., Catania J., Di Giovanni S., Muratoglu S., Perez R., Swartzbeck A., Quong A.A., Zhang X., Beerman T., Pestell R.G., Avantaggiati M.L. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 2006, 173:533-544.
33. Imbriano C., Gurtner A., Cocchiarella F., Di Agostino S., Basile V., Gostissa M., Dobbelstein M., Del Sal G., Piaggio G., Mantovani R. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol. Cell. Biol. 2005, 25:3737-3751.
34. Chao C., Wu Z., Mazur S.J., Borges H., Rossi M., Lin T., Wang J.Y., Anderson C.W., Appella E., Xu Y. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 2006, 26:6859-6869.
35. Lee Y.H., Seo D., Choi K.J., Andersen J.B., Won M.A., Kitade M., Gomez-Quiroz L.E., Judge A.D., Marquardt J.U., Raggi C., Conner E.A., MacLachlan I., Factor V.M., Thorgeirsson S. Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res. 2014, 74:4752-4761.
36. LeBoeuf M., Terrell A., Trivedi S., Sinha S., Epstein J.A., Olson E.N., Morrisey E.E., Millar S.E. Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. Dev. Cell 2010, 19:807-818.
37. Toledo F., Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6:909-923.
38. Batchelor E., Loewer A., Lahav G. The ups and downs of p53: understanding protein dynamics in single cells. Nat. Rev. Cancer 2009, 9:371-377.
39. Goldbeter A., Gerard C., Gonze D., Leloup J.C., Dupont G. Systems biology of cellular rhythms. FEBS Lett. 2012, 586:2955-2965.
40. Krämer O.H., Zhu P., Ostendorff H.P., Golebiewski M., Tiefenbach J., Peters M.A., Brill B., Groner B., Bach I., Heinzel T., Göttlicher M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003, 22:3411-3420.
41. Zhang J., Kan S., Huang B., Hao Z., Mak T.W., Zhong Q. Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2. Genes Dev. 2011, 25:2610-2618.
42. Inoue S., Hao Z., Elia A.J., Cescon D., Zhou L., Silvester J., Snow B., Harris I.S., Sasaki M., Li W.Y., Itsumi M., Yamamoto K., Ueda T., Dominguez-Brauer C., Gorrini C., Chio I.I., Haight J., You-Ten A., McCracken S., Wakeham A., Ghazarian D., Penn L.J., Melino G., Mak T.W. Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes Dev. 2013, 27:1101-1114.
43. Bhandari D.R., Seo K.W., Jung J.W., Kim H.S., Yang S.R., Kang K.S. The regulatory role of c-MYC on HDAC2 and PcG expression in human multipotent stem cells. J. Cell. Mol. Med. 2011, 15:1603-1614.
44. Zhu P., Martin E., Mengwasser J., Schlag P., Janssen K.P., Göttlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004, 5:455-463.
45. Adhikary S., Marinoni F., Hock A., Hulleman E., Popov N., Beier R., Bernard S., Quarto M., Capra M., Goettig S., Kogel U., Scheffner M., Helin K., Eilers M. The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 2005, 123:409-421.
46. Chen D., Kon N., Li M., Zhang W., Qin J., Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005, 121:1071-1083.
47. Krämer O.H., Müller S., Buchwald M., Reichardt S., Heinzel T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. FASEB J. 2008, 22:1369-1379.
48. Fiucci G., Beaucourt S., Duflaut D., Lespagnol A., Stumptner-Cuvelette P., Geant A., Buchwalter G., Tuynder M., Susini L., Lassalle J.M., Wasylyk C., Wasylyk B., Oren M., Amson R., Telerman A. Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3510-3515.
49. Winter M., Sombroek D., Dauth I., Moehlenbrink J., Scheuermann K., Crone J., Hofmann T.G. Control of HIPK2 stability by ubiquitin ligase siah-1 and checkpoint kinases ATM and ATR. Nat. Cell Biol. 2008, 10:812-824.
50. Kong X., Peng B., Yang Y., Zhang P., Qin B., Han D., Wang C., Dang Y., Liu J.O., Yu L. p53 represses transcription of RING finger LIM domain-binding protein RLIM through Sp1. PLoS ONE 2013, 8:e62832.
51. Krämer O.H., Stauber R.H., Bug G., Hartkamp J., Knauer S.K. SIAH proteins: critical roles in leukemogenesis. Leukemia 2013, 27:792-802.
52. Grishina I., Debus K., Garcia-Limones C., Schneider C., Shresta A., Garcia C., Calzado M.A., Schmitz M.L. SIAH-mediated ubiquitination and degradation of acetyl-transferases regulate the p53 response and protein acetylation. Biochim. Biophys. Acta 2012, 1823:2287-2296.
53. Chan P., Moller A., Liu M.C., Sceneay J.E., Wong C.S., Waddell N., Huang K.T., Dobrovic A., Millar E.K., O'Toole S.A., McNeil C.M., Sutherland R.L., Bowtell D.D., Fox S.B. The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Res. 2011, 13:R19.
54. Müller S., Chen Y., Ginter T., Schäfer C., Buchwald M., Schmitz L.M., Klitzsch J., Schutz A., Haitel A., Schmid K., Moriggl R., Kenner L., Friedrich K., Haan C., Petersen I., Heinzel T., Krämer O.H. SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget 2014, 5:3184-3196.
55. Martens J.H., Stunnenberg H.G. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett. 2010, 584:2662-2669.
56. Saeed S., Logie C., Stunnenberg H.G., Martens J.H. Genome-wide functions of PML-RARalpha in acute promyelocytic leukaemia. Br. J. Cancer 2011, 104:554-558.
57. Mitelman F., Johansson B., Mertens F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 2007, 7:233-245.
58. Heideman M.R., Wilting R.H., Yanover E., Velds A., de Jong J., Kerkhoven R.M., Jacobs H., Wessels L.F., Dannenberg J.H. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood 2013, 121:2038-2050.
59. Dovey O.M., Foster C.T., Conte N., Edwards S.A., Edwards J.M., Singh R., Vassiliou G., Bradley A., Cowley S.M. Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood 2013, 121:1335-1344.
60. Boucheron N., Tschismarov R., Goeschl L., Moser M.A., Lagger S., Sakaguchi S., Winter M., Lenz F., Vitko D., Breitwieser F.P., Muller L., Hassan H., Bennett K.L., Colinge J., Schreiner W., Egawa T., Taniuchi I., Matthias P., Seiser C., Ellmeier W. CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2. Nat. Immunol. 2014, 15:439-448.
61. Wilting R.H., Yanover E., Heideman M.R., Jacobs H., Horner J., van der Torre J., DePinho R.A., Dannenberg J.H. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 2010, 29:2586-2597.
62. Kurosawa K., Lin W., Ohta K. Distinct roles of HDAC1 and HDAC2 in transcription and recombination at the immunoglobulin loci in the chicken B cell line DT40. J. Biochem. 2010, 148:201-207.
63. Yamaguchi T., Cubizolles F., Zhang Y., Reichert N., Kohler H., Seiser C., Matthias P. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 2010, 24:455-469.
64. Bradbury C.A., Khanim F.L., Hayden R., Bunce C.M., White D.A., Drayson M.T., Craddock C., Turner B.M. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19:1751-1759.
65. Matthias P. Too much or too little, how much HDAC activity is good for you?. Blood 2013, 121:1930-1931.
66. Santoro F., Botrugno O.A., Dal Zuffo R., Pallavicini I., Matthews G.M., Cluse L., Barozzi I., Senese S., Fornasari L., Moretti S., Altucci L., Pelicci P.G., Chiocca S., Johnstone R.W., Minucci S. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 2013, 121:3459-3468.
67. Hallas J., Friis S., Bjerrum L., Stovring H., Narverud S.F., Heyerdahl T., Gronbaek K., Andersen M. Cancer risk in long-term users of valproate: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1714-1719.
68. Singh G., Bell G.S., Driever P.H., Sander J.W. Cancer risk in people with epilepsy using valproate-sodium. Acta Neurol. Scand. 2012, 125:234-240.
69. Weichert W., Röske A., Niesporek S., Noske A., Buckendahl A.C., Dietel M., Gekeler V., Boehm M., Beckers T., Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 2008, 14:1669-1677.
70. Huang B.H., Laban M., Leung C.H., Lee L., Lee C.K., Salto-Tellez M., Raju G.C., Hooi S.C. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005, 12:395-404.
71. Stypula-Cyrus Y., Damania D., Kunte D.P., Cruz M.D., Subramanian H., Roy H.K., Backman V. HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS ONE 2013, 8:e64600.
72. Jin J.S., Tsao T.Y., Sun P.C., Yu C.P., Tzao C. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. Pathol. Oncol. Res. 2012, 18:713-720.
73. Gräff J., Rei D., Guan J.S., Wang W.Y., Seo J., Hennig K.M., Nieland T.J., Fass D.M., Kao P.F., Kahn M., Su S.C., Samiei A., Joseph N., Haggarty S.J., Delalle I., Tsai L.H. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
74. Zimmermann S., Kiefer F., Prudenziati M., Spiller C., Hansen J., Floss T., Wurst W., Minucci S., Göttlicher M. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res. 2007, 67:9047-9054.
75. Ravillah D., Mohammed A., Qian L., Brewer M., Zhang Y., Biddick L., Steele V.E., Rao C.V. Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+mouse intestinal tumorigenesis. J. Pharmacol. Exp. Ther. 2014, 348:59-68.
76. Ropero S., Ballestar E., Alaminos M., Arango D., Schwartz S., Esteller M. Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene 2008, 27:4008-4012.
77. Ropero S., Fraga M.F., Ballestar E., Hamelin R., Yamamoto H., Boix-Chornet M., Caballero R., Alaminos M., Setien F., Paz M.F., Herranz M., Palacios J., Arango D., Orntoft T.F., Aaltonen L.A., Schwartz S., Esteller M. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 2006, 38:566-569.
78. Hanigan C.L., Van Engeland M., De Bruine A.P., Wouters K.A., Weijenberg M.P., Eshleman J.R., Herman J.G. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 2008, 135:1654-1664. (e1652).
79. Kawaguchi M., Banno K., Yanokura M., Kobayashi Y., Kishimi A., Ogawa S., Kisu I., Nomura H., Hirasawa A., Susumu N., Aoki D. Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer. Int. J. Oncol. 2009, 35:977-982.
80. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat. Rev. Cancer 2012, 12:323-334.
81. Mariadason J.M. Making sense of HDAC2 mutations in colon cancer. Gastroenterology 2008, 135:1457-1459.
82. Sammalkorpi H., Alhopuro P., Lehtonen R., Tuimala J., Mecklin J.P., Jarvinen H.J., Jiricny J., Karhu A., Aaltonen L.A. Background mutation frequency in microsatellite-unstable colorectal cancer. Cancer Res. 2007, 67:5691-5698.
83. Ree A.H., Folkvord S., Flatmark K. HDAC2 deficiency and histone acetylation. Nat. Genet. 2008, 40:812-813. (author reply 813).
84. Kelly R.D., Cowley S.M. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem. Soc. Trans. 2013, 41:741-749.
85. Barckhausen C., Roos W.P., Naumann S.C., Kaina B. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair. Oncogene 2014, 33:1964-1974.
86. Heinzel T., Krämer O.H. Pharmacodynamic markers for histone deacetylase inhibitor development. Drug Discov. Today Dis. Mech. 2007, 4:277-283.
87. Bach Knudsen K.E., Serena A., Canibe N., Juntunen K.S. New insight into butyrate metabolism. Proc. Nutr. Soc. 2003, 62:81-86.
88. McIntyre A., Gibson P.R., Young G.P. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut 1993, 34:386-391.
89. Sun P.C., Tzao C., Chen B.H., Liu C.W., Yu C.P., Jin J.S. Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells. J. Biomed. Sci. 2010, 17:76.
90. Kunte D.P., Wali R.K., Koetsier J.L., Hart J., Kostjukova M.N., Kilimnik A.Y., Pyatkin I.G., Strelnikova S.R., Roy H.K. Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation. FEBS Lett. 2005, 579:3497-3502.
91. Longley D.B., Harkin D.P., Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3:330-338.
92. Inoue T., Hibi K., Nakayama G., Komatsu Y., Fukuoka T., Kodera Y., Ito K., Akiyama S., Nakao A. Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer. J. Gastroenterol. 2005, 40:143-147.
93. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., Lenz H.J., Leichman C.G., Leichman L., Diasio R.B., Danenberg P.V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 2000, 6:1322-1327.
94. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995, 55:1407-1412.
95. Fazzone W., Wilson P.M., Labonte M.J., Lenz H.J., Ladner R.D. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int. J. Cancer 2009, 125:463-473.
96. Fritzsche F.R., Weichert W., Roske A., Gekeler V., Beckers T., Stephan C., Jung K., Scholman K., Denkert C., Dietel M., Kristiansen G. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 2008, 8:381.
97. Noh J.H., Bae H.J., Eun J.W., Shen Q., Park S.J., Kim H.S., Nam B., Shin W.C., Lee E.K., Lee K., Jang J.J., Park W.S., Lee J.Y., Nam S.W. HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT. Cancer Res. 2014, 74:1728-1738.
98. Quint K., Agaimy A., Di Fazio P., Montalbano R., Steindorf C., Jung R., Hellerbrand C., Hartmann A., Sitter H., Neureiter D., Ocker M. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch. 2011, 459:129-139.
99. Mutze K., Langer R., Becker K., Ott K., Novotny A., Luber B., Hapfelmeier A., Gottlicher M., Hofler H., Keller G. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann. Surg. Oncol. 2010, 17:3336-3343.
100. Weichert W., Röske A., Gekeler V., Beckers T., Ebert M.P., Pross M., Dietel M., Denkert C., Rocken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008, 9:139-148.
101. Song J., Noh J.H., Lee J.H., Eun J.W., Ahn Y.M., Kim S.Y., Lee S.H., Park W.S., Yoo N.J., Lee J.Y., Nam S.W. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005, 113:264-268.
102. Regel I., Merkl L., Friedrich T., Burgermeister E., Zimmermann W., Einwachter H., Herrmann K., Langer R., Rocken C., Hofheinz R., Schmid R., Ebert M.P. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2. Gastroenterology 2012, 143:99-109. (e110).
103. Kim J.K., Noh J.H., Eun J.W., Jung K.H., Bae H.J., Shen Q., Kim M.G., Chang Y.G., Kim S.J., Park W.S., Lee J.Y., Borlak J., Nam S.W. Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer. Mol. Cancer Res. 2013, 11:62-73.
104. Lehmann A., Denkert C., Budczies J., Buckendahl A.C., Darb-Esfahani S., Noske A., Muller B.M., Bahra M., Neuhaus P., Dietel M., Kristiansen G., Weichert W. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009, 9:395.
105. Fritsche P., Seidler B., Schüler S., Schnieke A., Göttlicher M., Schmid R.M., Saur D., Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009, 58:1399-1409.
106. Schneider G., Krämer O.H., Schmid R.M., Saur D. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. J. Gastrointest. Cancer 2011, 42:85-92.
107. Yang F.Q., Liu M., Yang F.P., Che J., Li W., Zhai W., Wang G.C., Zheng J.H., Li X. VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1alpha. Mol. Biol. Rep. 2014, 41:1511-1518.
108. Kim H.S., Chang Y.G., Bae H.J., Eun J.W., Shen Q., Park S.J., Shin W.C., Lee E.K., Park S., Ahn Y.M., Park W.S., Lee J.Y., Nam S.W. Oncogenic potential of CK2alpha and its regulatory role in EGF-induced HDAC2 expression in human liver cancer. FEBS J. 2014, 281:851-861.
109. Weichert W., Boehm M., Gekeler V., Bahra M., Langrehr J., Neuhaus P., Denkert C., Imre G., Weller C., Hofmann H.P., Niesporek S., Jacob J., Dietel M., Scheidereit C., Kristiansen G. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br. J. Cancer 2007, 97:523-530.
110. Schüler S., Fritsche P., Diersch S., Arlt A., Schmid R.M., Saur D., Schneider G. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol. Cancer 2010, 9:80.
111. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
112. Ploner C., Kofler R., Villunger A. Noxa: at the tip of the balance between life and death. Oncogene 2008, 27(Suppl. 1):S84-S92.
113. Martin A.G., Trama J., Crighton D., Ryan K.M., Fearnhead H.O. Activation of p73 and induction of Noxa by DNA damage requires NF-kappa B. Aging (Albany NY) 2009, 1:335-349.
114. Labisso W.L., Wirth M., Stojanovic N., Stauber R.H., Schnieke A., Schmid R.M., Krämer O.H., Saur D., Schneider G. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle 2012, 11:1593-1602.
115. Bai L., Merchant J.L. A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. FEBS Lett. 2007, 581:5904-5910.
116. Wu Z.Z., Sun N.K., Chao C.C. Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis. J. Cell. Physiol. 2011, 226:2415-2428.
117. Kanai Y. Overexpression of HDACs: a prognostic marker for gastric cancer identified by tissue microarray. Lancet Oncol. 2008, 9:91-93.
118. Yao H., Rahman I. Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammaging and COPD. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 303:L557-L566.
119. Barnes P.J. Histone deacetylase-2 and airway disease. Ther. Adv. Respir. Dis. 2009, 3:235-243.
120. Jung K.H., Noh J.H., Kim J.K., Eun J.W., Bae H.J., Xie H.J., Chang Y.G., Kim M.G., Park H., Lee J.Y., Nam S.W. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J. Cell. Biochem. 2012, 113:2167-2177.
121. Brodie S.A., Li G., El-Kommos A., Kang H., Ramalingam S.S., Behera M., Gandhi K., Kowalski J., Sica G.L., Khuri F.R., Vertino P.M., Brandes J.C. Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer Prev. Res. (Phila) 2014, 7:351-361.
122. Han Y., Zhang Y., Yang L.H., Mi X.Y., Dai S.D., Li Q.C., Xu H.T., Yu J.H., Li G., Zhao J., Han C., Yuan X.M., Wang E.H. X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer. Radiat. Oncol. 2012, 7:183.
123. Mizuno S., Yasuo M., Bogaard H.J., Kraskauskas D., Natarajan R., Voelkel N.F. Inhibition of histone deacetylase causes emphysema. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300:L402-L413.
124. Londhe V.A., Sundar I.K., Lopez B., Maisonet T.M., Yu Y., Aghai Z.H., Rahman I. Hyperoxia impairs alveolar formation and induces senescence through decreased histone deacetylase activity and up-regulation of p21 in neonatal mouse lung. Pediatr. Res. 2011, 69:371-377.
125. Polyak K. Breast cancer: origins and evolution. J. Clin. Invest. 2007, 117:3155-3163.
126. Müller B.M., Jana L., Kasajima A., Lehmann A., Prinzler J., Budczies J., Winzer K.J., Dietel M., Weichert W., Denkert C. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 2013, 13:215.
127. Harms K.L., Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 2007, 67:3145-3152.
128. Tian B., Liu J., Liu B., Dong Y., Liu J., Song Y., Sun Z. p53 Suppresses lung resistance-related protein expression through Y-box binding protein 1 in the MCF-7 breast tumor cell line. J. Cell. Physiol. 2011, 226:3433-3441.
129. Lee M.H., Na H., Kim E.J., Lee H.W., Lee M.O. Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1. Oncogene 2012, 31:5099-5107.
130. Bicaku E., Marchion D.C., Schmitt M.L., Munster P.N. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res. 2008, 68:1513-1519.
131. Li D.Q., Pakala S.B., Nair S.S., Eswaran J., Kumar R. Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. Cancer Res. 2012, 72:387-394.
132. Toh Y., Nicolson G.L. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin. Exp. Metastasis 2009, 26:215-227.
133. Schneider J., Gonzalez-Roces S., Pollan M., Lucas R., Tejerina A., Martin M., Alba A. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res. 2001, 3:183-191.
134. Aritas Y., Kara O., Abdulkadir B., Sakrak O. The importance of the tumor basement membrane laminin and LRP/MVP receptors in breast cancer. Breast J. 2003, 9:339-340.
135. Mossink M.H., van Zon A., Franzel-Luiten E., Schoester M., Kickhoefer V.A., Scheffer G.L., Scheper R.J., Sonneveld P., Wiemer E.A. Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res. 2002, 62:7298-7304.
136. Berger W., Steiner E., Grusch M., Elbling L., Micksche M. Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell. Mol. Life Sci. 2009, 66:43-61.
137. Munster P., Marchion D., Bicaku E., Lacevic M., Kim J., Centeno B., Daud A., Neuger A., Minton S., Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin. Cancer Res. 2009, 15:2488-2496.
138. Munster P.N., Thurn K.T., Thomas S., Raha P., Lacevic M., Miller A., Melisko M., Ismail-Khan R., Rugo H., Moasser M., Minton S.E. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 2011, 104:1828-1835.
139. Marchion D.C., Bicaku E., Turner J.G., Schmitt M.L., Morelli D.R., Munster P.N. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol. Cancer Ther. 2009, 8:794-801.
140. Koster M.I. p63 in skin development and ectodermal dysplasias. J. Invest. Dermatol. 2010, 130:2352-2358.
141. Qian Y., Jung Y.S., Chen X. DeltaNp63, a target of DEC1 and histone deacetylase 2, modulates the efficacy of histone deacetylase inhibitors in growth suppression and keratinocyte differentiation. J. Biol. Chem. 2011, 286:12033-12041.
142. Qian Y., Zhang J., Yan B., Chen X. DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J. Biol. Chem. 2008, 283:2896-2905.
143. Ramsey M.R., He L., Forster N., Ory B., Ellisen L.W. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res. 2011, 71:4373-4379.
144. Chang H.H., Chiang C.P., Hung H.C., Lin C.Y., Deng Y.T., Kuo M.Y. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 2009, 45:610-614.
145. Theocharis S., Klijanienko J., Giaginis C., Rodriguez J., Jouffroy T., Girod A., Alexandrou P., Sastre-Garau X. Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J. Oral Pathol. Med. 2011, 40:706-714.
146. Fitzgerald O'Connor E.J., Badshah I.I., Addae L.Y., Kundasamy P., Thanabalasingam S., Abioye D., Soldin M., Shaw T.J. Histone deacetylase 2 is upregulated in normal and keloid scars. J. Invest. Dermatol. 2012, 132:1293-1296.
147. Kim Y., Park H., Park D., Lee Y.S., Choe J., Hahn J.H., Lee H., Kim Y.M., Jeoung D. Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs. J. Biol. Chem. 2010, 285:25957-25968.
148. Guan J.S., Haggarty S.J., Giacometti E., Dannenberg J.H., Joseph N., Gao J., Nieland T.J., Zhou Y., Wang X., Mazitschek R., Bradner J.E., DePinho R.A., Jaenisch R., Tsai L.H. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009, 459:55-60.
149. Zhang J., Chen X. DeltaNp73 modulates nerve growth factor-mediated neuronal differentiation through repression of TrkA. Mol. Cell. Biol. 2007, 27:3868-3880.
150. Casciano I., Mazzocco K., Boni L., Pagnan G., Banelli B., Allemanni G., Ponzoni M., Tonini G.P., Romani M. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 2002, 9:246-251.
151. Gaub P., Tedeschi A., Puttagunta R., Nguyen T., Schmandke A., Di Giovanni S. HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/p300 and P/CAF-dependent p53 acetylation. Cell Death Differ. 2010, 17:1392-1408.
152. Lucio-Eterovic A.K., Cortez M.A., Valera E.T., Motta F.J., Queiroz R.G., Machado H.R., Carlotti C.G., Neder L., Scrideli C.A., Tone L.G. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008, 8:243.
153. Frumm S.M., Fan Z.P., Ross K.N., Duvall J.R., Gupta S., VerPlank L., Suh B.C., Holson E., Wagner F.F., Smith W.B., Paranal R.M., Bassil C.F., Qi J., Roti G., Kung A.L., Bradner J.E., Tolliday N., Stegmaier K. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem. Biol. 2013, 20:713-725.
154. Lodrini M., Oehme I., Schroeder C., Milde T., Schier M.C., Kopp-Schneider A., Schulte J.H., Fischer M., De Preter K., Pattyn F., Castoldi M., Muckenthaler M.U., Kulozik A.E., Westermann F., Witt O., Deubzer H.E. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res. 2013, 41:6018-6033.
155. Tang H., Bian Y., Tu C., Wang Z., Yu Z., Liu Q., Xu G., Wu M., Li G. The miR-183/96/182 cluster regulates oxidative apoptosis and sensitizes cells to chemotherapy in gliomas. Curr. Cancer Drug Targets 2013, 13:221-231.
156. Yin C.K., Fu Q. Expressions of HDAC1 and HDAC2 in prostate cancer and their clinical implications. Zhonghua Nan Ke Xue 2013, 19:699-703.
157. Weichert W., Röske A., Gekeler V., Beckers T., Stephan C., Jung K., Fritzsche F.R., Niesporek S., Denkert C., Dietel M., Kristiansen G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 2008, 98:604-610.
158. Roy S., Packman K., Jeffrey R., Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ. 2005, 12:482-491.
159. Sonnemann J., Marx C., Becker S., Wittig S., Palani C.D., Krämer O.H., Beck J.F. p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. Br. J. Cancer 2014, 110:656-667.
160. Zhao Y., Lu S., Wu L., Chai G., Wang H., Chen Y., Sun J., Yu Y., Zhou W., Zheng Q., Wu M., Otterson G.A., Zhu W.G. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol. Cell. Biol. 2006, 26:2782-2790.
161. Weichert W., Denkert C., Noske A., Darb-Esfahani S., Dietel M., Kalloger S.E., Huntsman D.G., Kobel M. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 2008, 10:1021-1027.
162. Fakhry H., Miyamoto T., Kashima H., Suzuki A., Ke H., Konishi I., Shiozawa T. Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells. Hum. Pathol. 2010, 41:848-858.
163. Jin K.L., Pak J.H., Park J.Y., Choi W.H., Lee J.Y., Kim J.H., Nam J.H. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J. Gynecol. Oncol. 2008, 19:185-190.
164. Gu Y., Yang P., Shao Q., Liu X., Xia S., Zhang M., Xu H., Shao Q. Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues. Oncol. Lett. 2013, 5:452-458.
165. Lin Z., Bazzaro M., Wang M.C., Chan K.C., Peng S., Roden R.B. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin. Cancer Res. 2009, 15:570-577.
166. Colon-Diaz M., Baez-Vega P., Garcia M., Ruiz A., Monteiro J.B., Fourquet J., Bayona M., Alvarez-Garriga C., Achille A., Seto E., Flores I. HDAC1 and HDAC2 are differentially expressed in endometriosis. Reprod. Sci. 2012, 19:483-492.
167. Hrzenjak A., Moinfar F., Kremser M.L., Strohmeier B., Staber P.B., Zatloukal K., Denk H. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 2006, 5:2203-2210.
168. Pacheco M., Nielsen T.O. Histone deacetylase 1 and 2 in mesenchymal tumors. Mod. Pathol. 2012, 25:222-230.
169. Li Y., Li X., Fan G., Fukushi J., Matsumoto Y., Iwamoto Y., Zhu Y. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Lett. 2012, 320:14-22.
170. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
171. Johnson R.F., Perkins N.D. Nuclear factor-kappaB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends Biochem. Sci. 2012, 37:317-324.
172. Kim H.S., Lee M.S. STAT1 as a key modulator of cell death. Cell. Signal. 2007, 19:454-465.
173. Stephanou A., Latchman D.S. STAT-1: a novel regulator of apoptosis. Int. J. Exp. Pathol. 2003, 84:239-244.
174. Szczepanek K., Lesnefsky E.J., Larner A.C. Multi-tasking: nuclear transcription factors with novel roles in the mitochondria. Trends Cell Biol. 2012, 22:429-437.
175. Dai C., Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol. Med. 2010, 16:528-536.
176. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2:a001008.
177. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012, 26:1268-1286.
178. Shiloh Y., Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 2013, 14:197-210.
179. Wade M., Li Y.C., Wahl G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 2013, 13:83-96.
180. Forslund A., Zeng Z., Qin L.X., Rosenberg S., Ndubuisi M., Pincas H., Gerald W., Notterman D.A., Barany F., Paty P.B. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers. Mol. Cancer Res. 2008, 6:205-211.
181. Ellis L., Atadja P.W., Johnstone R.W. Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther. 2009, 8:1409-1420.
182. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17:330-339.
183. Wagner J.M., Hackanson B., Lubbert M., Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 2010, 1:117-136.
184. Eom G.H., Nam Y.S., Oh J.G., Choe N., Min H.K., Yoo E.K., Kang G., Nguyen V.H., Min J.J., Kim J.K., Lee I.K., Bassel-Duby R., Olson E.N., Park W.J., Kook H. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy. Circ. Res. 2014, 114:1133-1143.
185. Gruhn B., Naumann T., Gruner D., Walther M., Wittig S., Becker S., Beck J.F., Sonnemann J. The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. Leuk. Res. 2013, 37:1200-1207.
186. Moreno D.A., Scrideli C.A., Cortez M.A., de Paula Queiroz R., Valera E.T., da Silva Silveira V., Yunes J.A., Brandalise S.R., Tone L.G. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 2010, 150:665-673.
187. Tao Y.F., Pang L., Du X.J., Sun L.C., Hu S.Y., Lu J., Cao L., Zhao W.L., Feng X., Wang J., Wu D., Wang N., Ni J., Pan J. Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia. Int. J. Mol. Sci. 2013, 14:3376-3394.
188. Serrano E., Lasa A., Perea G., Carnicer M.J., Brunet S., Aventin A., Sierra J., Nomdedeu J.F. Acute myeloid leukemia subgroups identified by pathway-restricted gene expression signatures. Acta Haematol. 2006, 116:77-89.
189. Adams H., Fritzsche F.R., Dirnhofer S., Kristiansen G., Tzankov A. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opin. Ther. Targets 2010, 14:577-584.
190. Marquard L., Poulsen C.B., Gjerdrum L.M., de Nully Brown P., Christensen I.J., Jensen P.B., Sehested M., Johansen P., Ralfkiaer E. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009, 54:688-698.
191. Min S.K., Koh Y.H., Park Y., Kim H.J., Seo J., Park H.R., Cho S.J., Kim I.S. Expression of HAT1 and HDAC1, 2, 3 in diffuse large B-cell lymphomas peripheral T-cell lymphomas, and NK/T-cell lymphomas. Korean J. Pathol. 2012, 46:142-150.
192. Ashktorab H., Belgrave K., Hosseinkhah F., Brim H., Nouraie M., Takkikto M., Hewitt S., Lee E.L., Dashwood R.H., Smoot D. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig. Dis. Sci. 2009, 54:2109-2117.
193. Wang F., Qi Y., Li X., He W., Fan Q.X., Zong H. HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9. Clin. Invest. Med. 2013, 36:E87-E94.
194. Zhang N., Chen X., Liu H., Xi Y., Li S. The downregulation of HDAC2 expression in esophageal squamous cell carcinoma and its effect on biological features of EC9706 cells. TUMOR 2011, 31:886-892.
195. Noh J.H., Jung K.H., Kim J.K., Eun J.W., Bae H.J., Xie H.J., Chang Y.G., Kim M.G., Park W.S., Lee J.Y., Nam S.W. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS ONE 2011, 6:e28103.
196. Marquard L., Gjerdrum L.M., Christensen I.J., Jensen P.B., Sehested M., Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008, 53:267-277.
197. Hayashi A., Horiuchi A., Kikuchi N., Hayashi T., Fuseya C., Suzuki A., Konishi I., Shiozawa T. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int. J. Cancer 2010, 127:1332-1346.
198. Niegisch G., Knievel J., Koch A., Hader C., Fischer U., Albers P., Schulz W.A. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol. Oncol. 2013, 31:1770-1779.
199. Kerl K., Ries D., Unland R., Borchert C., Moreno N., Hasselblatt M., Jurgens H., Kool M., Gorlich D., Eveslage M., Jung M., Meisterernst M., Fruhwald M. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC Cancer 2013, 13:286.
200. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3003-3007.
201. Nakajima H., Kim Y.B., Terano H., Yoshida M., Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 1998, 241:126-133.
202. Göttlicher M., Minucci S., Zhu P., Krämer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20:6969-6978.
203. Suzuki T., Ando T., Tsuchiya K., Fukazawa N., Saito A., Mariko Y., Yamashita T., Nakanishi O. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 1999, 42:3001-3003.
204. Hess-Stumpp H., Bracker T.U., Henderson D., Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int. J. Biochem. Cell Biol. 2007, 39:1388-1405.
205. Candido E.P., Reeves R., Davie J.R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978, 14:105-113.
206. Davie J.R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 2003, 133:2485S-2493S.
207. Beck J., Fischer T., Rowinsky E., et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589: a novel histone deacetylase inhibitor [abstract]. Proc. Am. Soc. Clin. Oncol. 2004, 201.
208. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009, 280:233-241.
209. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265:17174-17179.
210. Vanhaecke T., Papeleu P., Elaut G., Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem. 2004, 11:1629-1643.
211. Lu Q., Wang D.S., Chen C.S., Hu Y.D., Chen C.S. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J. Med. Chem. 2005, 48:5530-5535.